PharmaNutra
€70.50Change from previous close: −0.98%Absolute change: −€0.70
At a glance
- Revenue growth
- +13.83%
- 2025 vs 2024
- Net income growth
- +20.44%
- 2025 vs 2024
- Net margin
- 15.0%
- 2024: 14.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 133 | 117 | 101 | 83.4 | — |
| Cost of revenue | 30.1 | 26.0 | 29.7 | 21.9 | — |
| Gross profit | 103 | 90.8 | 71.7 | 61.5 | — |
| Selling, general and administrative | 47.0 | 37.8 | 27.0 | 22.1 | — |
| Research and development | 0.8 | 1.3 | 1.2 | 0.5 | — |
| Operating income | 30.3 | 28.1 | 23.6 | 23.3 | — |
| EBIT | 30.9 | 28.2 | 24.1 | 23.5 | — |
| EBITDA | 34.3 | 32.2 | 27.2 | 24.6 | — |
| Interest expense | 0.7 | 1.1 | 0.8 | 0.1 | — |
| Pre-tax income | 30.2 | 27.2 | 23.3 | 23.4 | — |
| Income tax | 10.3 | 10.6 | 10.4 | 8.4 | — |
| Net income | 20.0 | 16.6 | 12.8 | 15.0 | — |
| Net income to common shareholders | 20.0 | 16.6 | 12.8 | 15.0 | — |
| Basic EPS | 2.09 | 1.73 | 1.33 | 1.56 | — |
| Diluted EPS | 2.09 | 1.73 | 1.33 | 1.56 | — |
| Average shares (basic) | 9.6 | 9.6 | 9.6 | 9.7 | — |
| Average shares (diluted) | 9.6 | 9.6 | 9.6 | 9.7 | — |